Vivus Inc
featured
Check out which companies are making headlines after the bell Tuesday:
» Read More
More
-
NEW YORK-- Weight loss drug maker Vivus Inc. said Tuesday it plans to sell $200 million in convertible senior debt due in 2020 in a private transaction. Vivus said the initial purchasers will have the option to buy another $30 million in notes, which are due May 1, 2020. Shares of Vivus lost 40 cents, or 3 percent, to $13.19 in morning trading.
-
MOUNTAIN VIEW, Calif.-- Obesity drug maker Vivus Inc. on Monday named two new directors to its board as it finds itself in a proxy fight. CEO of German drugmaker Boehringer Ingelheim from 2003 to 2011, and Plutzky has directed the vascular disease prevention program at Brigham and Women's Hospital in Boston since 1996..
-
NEW YORK, May 9- Three long-time favorites of the short-selling crowd are making those investors eat crow, as Tesla, Barnes& Noble and Green Mountain Coffee are racking up big gains, making an already painful year for contrarian investors even worse. Barnes& Noble shares rose 24 percent on reports of a possible acquisition of some of its assets by Microsoft.
-
**RADCOM LTD, $4.05, up 53 pct. **DELCATH SYSTEMS INC, $0.43, down 45 pct. **LINKEDIN CORP, $181.69, down 10 pct.
-
**RADCOM LTD, $4.05, up 53 pct. **DELCATH SYSTEMS INC, $0.43, down 45 pct. **LINKEDIN CORP, $181.69, down 10 pct.
-
**RADCOM LTD, $4.05, up 53 pct. **DELCATH SYSTEMS INC, $0.43, down 45 pct. **LINKEDIN CORP, $181.69, down 10 pct.
-
**RADCOM LTD, $4.05, up 53 pct. **LINKEDIN CORP, $181.69, down 10 pct. The U.S. Justice Department is suing the company and its hospice subsidiaries, including the biggest U.S. for-profit hospice chain, alleging false billings for Medicare hospice services.
-
**LINKEDIN CORP, $186.46, down 8 pct. **VIVUS INC, $13.28, up 3 pct. Arena said on Thursday that it pulled its application seeking approval for its anti-obesity treatment Belviq in the European Union, lowering competition for rival Vivus, whose obesity pill was recommended for European approval by regulators late last month.
-
**LINKEDIN CORP, $186.46, down 8 pct. **VIVUS INC, $13.28, up 3 pct. Arena said on Thursday that it pulled its application seeking approval for its anti-obesity treatment Belviq in the European Union, lowering competition for rival Vivus, whose obesity pill was recommended for European approval by regulators late last month.
-
**LINKEDIN CORP, Thursday close $201.67, down 9 pct premarket. **VIVUS INC, Thursday close $12.95, up 4 pct premarket.
-
**RADCOM LTD, $4.05, up 53 pct. **LINKEDIN CORP, $181.69, down 10 pct. The U.S. Justice Department is suing the company and its hospice subsidiaries, including the biggest U.S. for-profit hospice chain, alleging false billings for Medicare hospice services.
-
May 2- Arena Pharmaceuticals Inc withdrew an application to market its anti-obesity drug in the European Union, sending its shares down 15 percent in after-hours trading.
-
May 2- Arena Pharmaceuticals Inc withdrew an application to market its anti-obesity drug in the European Union, sending its shares down 15 percent in after-hours trading.
-
May 2- Arena Pharmaceuticals Inc withdrew an application to market its anti-obesity drug in the European Union, sending its shares down 15 percent in after-hours trading.
-
*First Manhattan comments on addition to vivus' board of directors. woefully short. a total board overhaul is necessary at Vivus ". *First Manhattan says it is the the largest shareholder of Vivus with.
-
*On April 26, board of co appointed Robert N. Wilson as a director of the. *In connection with wilson's appointment, board increased the authorized. number of directors from 6 to 7, from April 26, 2013.
-
Stocks fell as the broadest measure of U.S. economic growth fell short of expectations in the first quarter and Amazon.com gave a disappointing outlook. **CHEVRON CORP, $120.06, up 1.3 pct. **AMAZON.COM INC, $255.52, down 7 pct.
-
**PFIZER INC, $29.02, down 4.1 pct. **APPLE INC, $409.46, down 0.3 pct. Samsung Electronics Co Ltd grabbed more smartphone market share from arch rival Apple in the latest quarter, with sales of its phones jumping to account for one third of the global market, research firm IDC said.
-
**APPLE INC, Thursday close $408.38, down 0.3 pct premarket. Samsung Electronics Co Ltd grabbed more smartphone market share from arch rival Apple in the latest quarter, with sales of its phones jumping to account for one third of the global market, research firm IDC said.